PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of springeropenLink to Publisher's site
Pediatric Cardiology
 
Pediatr Cardiol. 2017; 38(2): 255–263.
Published online 2016 November 11. doi:  10.1007/s00246-016-1507-3
PMCID: PMC5331095

Early Complications After Percutaneous Closure of Atrial Septal Defect in Infants with Procedural Weight Less than 15 kg

Abstract

Atrial septal defect (ASD) is the most common congenital cardiac lesion accounting for 10–15% of all cardiac malformations. In the majority of cases, the secundum type of the ASD is closed percutaneously in the catheterization laboratory. Although transcatheter closure of ASD is considered safe and effective in pediatric patients, there are limited data regarding the efficacy and safety of device ASD closure in smaller infants. The aim of this study was to determine risk of complications within 72 h following device closure of ASD in children of body weight <15 kg compared to larger children. Overall 252 children who underwent transcatheter closure of ASD at Children’s Heart Centre in Lund, Sweden, between 1998 and 2015 were included. Data regarding demographics, comorbidity and complications occurring during and after device procedure until discharge were retrieved from the hospital’s databases. Echocardiographic data were obtained from the digital and videotape recordings. Nearly half of the study cohort (n = 112; 44%) had a procedural weight <15 (median 11.3) kg with a median procedural age of 2.02 years. Among this study group, 22 (9%) children had post-procedural in-hospital complications, of which 16 (7%) were considered as major and six (2%) considered as minor. No deaths occurred. There was no significant difference in of the occurrence of major or minor complications between the two groups (p = 0.32). Larger ASD was more often associated with minor complications, OR 1.37 (95% CI 0.99–1.89), which most often consisted of transient arrhythmias during or after the procedure. Percutaneous ASD device closure can be performed safely in low-weight infants with a risk of post-procedural in-hospital complications comparable to larger/older children. Nevertheless, careful considerations of the indications to device closure is needed, particularly in children with larger ASD, as recommended by the current international guidelines for ASD closure.

Keywords: Atrial septal defect, Infant, Follow-up, Septal device, Post-interventional complications

Background

Cardiovascular malformations affect approximately 800 children per year in Sweden [1, 2]. Atrial septal defect (ASD) is the most common congenital cardiac lesion accounting for 10–15% of all cardiovascular malformations [2].

Larger ASD causes a significant left-to-right shunt with subsequent volume load of the right side of the heart. If left untreated, particularly in children with comorbidities, changes in the pulmonary arterioles may lead to gradual rise in the pulmonary pressure and eventually irreversible arteriolar damage, which is known as Eisenmenger syndrome [3]. Surgery has been considered to be the standard treatment of ASD ever since the late 1960s with good long-term post-operative results [4, 5]. The first catheter-based closure of secundum ASD was described by King and Mills in 1976 [6]. Transcatheter closure of ASD has gradually become more common and has been associated with less complications and shorter hospitalization [7, 8]. Today, the transcatheter approach is considered safe and effective, with few but non-negligible short- and long-term adverse events [9].

Asymptomatic infants with a significant ASD shunt are typically followed until they have grown to an acceptable age and size. Recent guidelines recommend transcatheter closure after the age of 2, although common practice suggests a weight over 15 kg [10]. Symptomatic infants, such as those born prematurely, with failure to thrive or with additional comorbidity or need for respiratory support, may benefit from early ASD closure in order to improve their clinical status [11, 12]. Refinements in the device configuration and material used during catheterization have contributed to improved procedural safety even in small children with severe clinical picture [13, 14]. In older children and adults, increased ratio of the ASD diameter/weight ratio and deficient or absent aortic rim have been associated with increased frequency of adverse events following transcatheter ASD closure [15, 16]. Previous studies on the efficacy and safety in children with small body weight have focused on risk factors such as ASD size, procedural body weight and age [13, 14, 17, 18]. However, other factors such as cardiac and other comorbidity, genetic abnormalities, premature birth and pulmonary function including chronic lung disease (CLD) may influence the risk of in-hospital adverse complications following ASD device closure.

The aim of this study was to assess the risk of major and minor complications following percutaneous transcatheter device closure of ASD in children with procedural weight <15 kg compared to larger children. Other potential risk factors such as cardiac and other comorbidities including premature birth were also taken into account.

Study Population and Methods

All children under the age of 18 years who underwent transcatheter ASD closure between 1998 and 2015 at the Skåne University Hospital in Lund, Sweden, were included in the study. Demographic information, such as age and weight at procedure, gestational age at birth and type of device, as well as information on complications and comorbidity was retrieved from medical records, from the Swedish Registry for Congenital Heart Disease (SWEDCON) and from the Swedish National Birth Registry (MFR) [19, 20]. MFR was established in 1973 and includes data on more than 99% of all births in Sweden [21]. Information on ASD size was retrieved from echocardiographic examinations. Comorbidity, including other cardiac defects, genetic abnormalities and other diseases, is retrieved from medical journals and classified according to Table 1. Gestational age was estimated by ultrasonic prenatal examination and retrieved from MFR register. Premature birth was defined as birth at <37 gestational weeks.

Table 1
Classification of comorbidity

Echocardiography

Echocardiographic data were retrieved from stored videotapes and digital examinations. The largest diameter of the ASD was measured from transesophageal echocardiography (TEE) images, being expressed in millimeter. All measurements were made by two investigators with intraobserver and interobserver variability of 3.0 and 2.7%, respectively.

The following indices were used:

  1. The ASD diameter/weight ratio was calculated using the largest measured ASD diameter (from TEE) divided by the child’s weight at the procedure. The children were thereafter categorized in two groups using a cutoff ratio of 1.2. This value was earlier shown to be a risk factor for post-procedural complications [15, 18].
  2. The ASD diameter/BSA ratio was calculated using the largest measured ASD diameter (from TTE) divided by the child’s BSA at the procedure. The body surface area (BSA) was calculated using Haycock geometrical formula [22].

Post-procedural complications were grouped into minor and major complications according to Bartakian et al. [17]. All complications occurring within the first 72 h after procedure or before discharge are classified and described in Table 2.

Table 2
Classification of complications

Statistical Analyses

Demographic data were analyzed using Student’s t test (unpaired two-sided) for parametrically distributed variables and Mann–Whitney U test for nonparametric distributed variables with a p value of <0.01 and Chi-squared test with a p value of <0.05 considered as statistically significant.

Demographic data are presented as mean and standard deviation (Std.) for parametric variables and as median and range for nonparametric variables.

Conditional logistic regression was preformed to evaluate the association between major and minor complication for children <15 kg at procedure and premature birth, cardiac and non-cardiac comorbidities, chromosomal abnormalities, ASD size, ASD diameter-to-weight ratio, BSA and ASD diameter-to-BSA ratio. Maximum likelihood estimates of the odds ratio (OR) and 95% confidence interval (CI) were obtained, taking into account potential confounding factors. The IBM SPSS Statistics, version 23 software (IBM Corporation, New York, USA), was used to fit the conditional logistic model.

The study was approved by the Ethics Committee for Human Research at the Lund University (D-nr 2015/559) in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments or comparable ethic standards.

Results

In total, 252 children underwent ASD device closure at the Skåne University Hospital in Lund between 1998 and 2015. Their mean age was 5.36 (Std. 4.44) years, median weight was 15.60 (range 4.78–87.50) kg, and the mean ASD size was 12.15 mm (Std. 4.31 mm). The overall female-to-male ratio was 1.7:1. The demographic characteristics are shown in Table 3.

Table 3
Demographic characteristics of all children

Of these, 112 (44%) children had a procedural weight of <15 kg. Children ≤15 kg had a median weight of 11.30 (range 4.78–14.80) kg, whereas children >15 kg had a median weight of 23.50 (range 15.00–87.50) kg. Children ≤15 kg were younger with a mean age of 2.02 (Std. 1.00) years compared to children >15 kg with mean age of 8.03 (Std. 4.33) years (p < 0.00).

The overall comorbidity was present in 65 (26%) children. This included other cardiac defects in 22 (9%) children, genetic comorbidity in 25 (10%) and other in 31 (12%). Comorbidity was more frequent 42 (38%) in the group of children ≤15 kg compared to 23 (16%) in children >15 kg (p < 0.001). In total, 42 (17%) children were born preterm. Data on gestational week at birth were missing in 36 cases (14%), as these children were born abroad. Data on comorbidity are summarized in Table 4.

Table 4
Demographic information in each subgroup

The Amplatzer septal occluder was the most common type of device used (n = 212). Other devices included Gore Occluder (n = 20), Cocoon/Vascular Innovations (n = 8), Occlutech Figulla Flex (n = 7), Cardioseal (n = 4) and Cardia Atriasept (n = 1).

Major complications were more common than minor complications, especially in the group of children ≤15 kg. The type of complications in each group and in all children is shown in Table 5.

Table 5
Type of complications in each subgroup and in all children

Echocardiography

ASD mean size by TEE was significantly smaller in children ≤15 kg 10.97 mm (Std 3.40 mm) compared to ASD size in children >15 kg 13.05 mm (Std. 4.72 mm) (p < 0.00). Also the device used was smaller 15.49 mm (Std. 4.83 mm) in children ≤15 kg compared to 20.07 mm (Std. 6.96 mm) in the other group (p < 0.000) (Table 4).

Post-procedural Complications

Post-procedural in-hospital complications occurred in 22 (9%) children. There were no in-hospital deaths. Major complications occurred in 16 (7%) children, whereas minor complications occurred in six (2%) children, all on the first post-procedural day.

Major complications occurred in 11 (10%) children of ≤15 kg weight, compared to six (4%) children of >15 kg, with significant difference between the groups (p = 0.04). Minor complications occurred in one (1%) among children of ≤15 kg weight, compared to six (4%) among children of >15 kg, with no significant difference between the groups (Table 6).

Table 6
Risk factors for major and minor complications

The majority of children (n = 242 (96%)) were discharged the day after the intervention. Six children were discharged within 1 week and 3 children within 2 weeks. One child was discharged 299 days after the ASD closure. Among children with late discharge, five suffered from post-procedural in-hospital complication (four major and one minor) and one child had fatal device erosion out of hospital 5 days after the procedure. In three of these children, there was no recorded post-procedural in-hospital complication. Down syndrome was present in 1 child, with a previous coarctation of the aorta, pulmonary hypertension and persistent ductus arteriosus, which delayed this patient from discharge. The child was hospitalized prior to the ASD closure due respiratory failure caused by a combination of congestive heart failure and pneumonia. By the time of intervention, the respiratory problems had resolved, and the delayed discharged was due to feeding support. One other child with chromosome 8 deletion, anal atresia, spherocytosis and respiratory failure needed continuous positive airway pressure and oxygen treatment 19 days prior to the ASD closure. After ASD closure, the respiratory support was continued and the child was extubated 26 h after the intervention. One child born preterm was discharged after 299 days of hospitalization. Prolonged hospitalization was mainly due to complex feeding, respiratory and neurological problems resulting in need of mechanical ventilation, tracheostomy and other care actions. One other child who was born preterm stayed more than 72 h in hospital following ASD device closure, due to severe respiratory problems related to tracheobronchomalacia. During this time, the child underwent tracheostomy and continuous mechanical ventilation. This child was also treated for multiple problems for months pre-intervention. Further, the child was treated for a suspected endocarditis, with a total hospital stay at several centers after the ASD closure of 299 days.

There was no significant association between any of the risk factors and major complication following ASD device closure. Neither was low weight, OR = 1.67 (95% CI 0.38–7.30), ASD diameter/weight ratio, OR = 0.92 (95% CI 0.13–6.63), nor ASD diameter/BSA ratio, OR = 1.05 (95% CI 0.96–1.16) associated with an increased risk of major complications in multivariate analysis (Table 7). An increased risk of minor complications was close to significant associated with a larger ASD size, OR = 1.37 (95% CI 0.99–1.89), after adjustments for confounding factors (Table 7).

Table 7
Risk of complications following ASD device closure, conditional logistic regression analyses

Discussion

Our retrospective survey of a large cohort of children with device closure of the ASD indicates a relatively low rate of early post-procedural complications in those weighing <15 kg. The risk of complications in this cohort of patients was not altered by the presence of additional comorbidity or large ASD size.

We found an overall post-procedural in-hospital complication rate of 8.7%, with 9.8% in the group of children of ≤15 kg compared to 7.1% among children of >15 kg, but no significant difference between the groups. This is in line with previous studies on complications following percutaneous ASD closure [9, 17].

In children ≤15 kg at the procedure, major complications were more frequent (10%) compared to children >15 kg (4%) at the procedure. However, we included discharge from hospital later than 24 h as a major complication, which accounted for 5 cases in our study. These children suffered from severe pre-procedural medical conditions and needed longer post-procedural care, unrelated to the device intervention. A complex medical history prior to ASD closure may thus lead to longer hospital stay and to several non-procedural-related complications such as feeding support and respiratory support. When excluding discharge later than 24 h as a major complication after ASD closure, the overall complication rate for the total study group dropped to 6.3% and the rate of major complications to 4.3%. This is in line with other studies [17]. Comorbidity was more common among children of ≤15 kg compared to children >15 kg. In four cases, a prolonged hospital stay post-intervention was associated with the compounded comorbidity. However, when recalculating complication frequencies without using prolonged hospital stay post-intervention as an event no significant difference in the frequencies of major complications was found.

Higher ASD diameter/weight ratio and ASD-to-device size ratio have been earlier associated with greater risk of peri-procedural complications [15, 18]. In our study, we adjusted risk estimations for minor as well as major complications for these and other potential risk factors. The ASD size and device size were larger among children >15 kg in our study. The ASD size-to-body weight ratio was doubled among the smaller children compared to those >15 kg. Neither ASD diameter/weight ratio nor ASD diameter/BSA ratio was associated with an increased risk of major or minor complications in our study. However, the risk of minor complications increased with larger ASD size, and this association remained near significant after adjustments for other risk factors OR = 1.37 (95% CI 0.99–1.89). No such risk was noticed for major complications. Increased frequency of minor complications, such as transient arrhythmias, following percutaneous closure of larger ASD (>15 mm) has been reported by others [23]. Altogether, four children in our study were identified with procedural-related arrhythmias, which did not need treatment.

A previous study concluded that device closure of ASD >20 mm in children <20 kg is safe with regard to the risk of major complications [24]. We performed subgroup analysis of the risk of in-hospital complication after closure of ASD >20 mm. Overall 14 (6%) children and only one (1%) child of ≤15 kg had an ASD diameter larger than 20 mm. The risk of post-procedural minor complications for these children was associated with OR = 44.87 (95% CI 2.29–877.95, p = 0.012) after adjustments for potential confounders. Even though this accounted for a small group of patients, the risk of minor complications indicated that careful intra- and post-procedural monitoring of these children is needed.

Most of the minor complications in our study were intraprocedural arrhythmias. Thus, our study supports the hypothesis that a combination of abnormally stretched atrial wall decreased myocardial mass and edema due to a large device may trigger transient arrhythmias [24, 25]. ASD is known to alter the atrial depolarization as well as the structure of the atria with increased risk of arrhythmias [26, 27]. Although closing the ASD may reduce the prevalence of atrial tachyarrhythmia [28], transient arrhythmias including supraventricular tachycardia, ectopy and atrioventricular block have been described following ASD closure.

Spontaneous closure of ASD <8 mm is known to occur during the first years of infancy, but some ASD may enlarge over time [29]. In our study, the cohort of children of ≤15 kg (ASD size 5–21 mm) might include some ASDs with a potential of spontaneous closure later in life. However, all children included in the study had right heart enlargement as sign of significant ASD shunt, so this possibility is less likely.

In our study, comorbidity was more common among the smaller children, which is in agreement with others [23]. Genetic abnormalities, including Down syndrome, was also more common among the smaller children in our study, 16% of children ≤15 kg compared to 5% of children >15 kg. Neither genetic nor cardiac comorbidity was associated with increased risk of complications. Down syndrome is known to increase risk of pulmonary hypertension as well as heart failure in the presence of shunt defects [30, 31]. The incidence of ASD among children with Down syndrome is 8–48% [32]. In our study, 15 (6%) of all children had Down syndrome.

Several earlier studies have showed that children suffering from Down syndrome with compound cardiovascular malformations may benefit from corrective surgery of ASD [31, 33, 34]. Our study indicates that percutaneous ASD closure can be preformed safe, but the patients with Down syndrome were few and larger studies are needed.

Cardiovascular malformations are twice as common among preterm infants compared to full-term infants and have an increased mortality rate [35, 36]. The overall incidence of ASD among prematurely born infants is unknown, but a delayed spontaneous closure of ASD has been noted [36]. In our study, 17% of all infants with ASD percutaneous closure were born preterm and occurred among the children ≤15 kg (23%) compared to those of >15 kg (16%), with nonsignificant difference between the groups. Larger studies are needed to determine the risk of ASD device closure among preterm born children.

Prematurely born infants may suffer from severe pulmonary complications in association with ASD and pulmonary hypertension even as adults [12, 3739]. Thus, prematurely born children may benefit from early percutaneous treatment to eliminating the left-to-right shunt [12, 3739]. Prematurity was not a risk factor in our study for neither minor nor major complications, indicating that prematurely born infants can be considered for percutaneous closure of ASD. Even if ASD closure is safe for prematurely born infants, longer follow-up studies are needed to determine the long-term safety and benefits of early ASD closure.

Our study is limited by its retrospective nature. Data are collected from medical journals, registers and echocardiographic examinations, and thus, there is a risk of selection bias and missing data. To reduce these risks, all echocardiographic data were retrieved by only two researches with very low intraobserver and interobserver variability. Further, the number of included children is substantial, contributing increased power.

Using already assigned entities of complications to either major or minor categories may strengthen the study in comparison with other. Lund is one of the three centers in Sweden where percutaneous treatment of ASD is performed. During the study period, only 3 interventionists preformed all ASD closures. This minimizes risk of selection bias due to different techniques and interventionist skills.

Conclusion

ASD closure in most infants with a bodyweight of below than 15 kg or less can be performed safely with a low risk of post-procedural in-hospital complications, but considerations due to non-negligible complications can occur and sufficient indication to benefit the closure in small infants must be carefully considered. Increased risk of minor complications after ASD closure was associated with an increasing size of ASD. Further studies are needed to establish the long-term safety of ASD closure via device on low-weight children with potential risk factors such as prematurity, cardiac and other comorbidities.

Acknowledgements

We would like to thank the SWEDCON register and its steering committee for sharing data, and we acknowledge all the pediatric cardiology doctors and nurses in Sweden.

Compliance with ethical standards

Compliance with ethical standards

Conflict of interest

The authors declare no conflicts of interest.

References

1. Hoffman JI, Kaplan S, Liberthson RR. Prevalence of congenital heart disease. Am Heart J. 2004;147:425–439. doi: 10.1016/j.ahj.2003.05.003. [PubMed] [Cross Ref]
2. van der Linde D, Konings EE, Slager MA, Witsenburg M, Helbing WA, Takkenberg JJ, Roos-Hesselink JW. Birth prevalence of congenital heart disease worldwide: a systematic review and meta-analysis. J Am Coll Cardiol. 2011;58:2241–2247. doi: 10.1016/j.jacc.2011.08.025. [PubMed] [Cross Ref]
3. Frank DB, Hanna BD. Pulmonary arterial hypertension associated with congenital heart disease and Eisenmenger syndrome: current practice in pediatrics. Minerva Pediatr. 2015;67(2):169–185. [PMC free article] [PubMed]
4. Meijboom F, Hess J, Szatmari A, Utens EM, McGhie J, Deckers JW, Roelandt JR, Bos E. Long-term follow-up (9–20 years) after surgical closure of atrial septal defect at a young age. Am J Cardiol. 1993;72(18):1431–1434. doi: 10.1016/0002-9149(93)90192-F. [PubMed] [Cross Ref]
5. Lewis FJ, Taufic M. Closure of atrial septal defects with the aid of hypothermia; experimental accomplishments and the report of one successful case. Surgery. 1953;33(1):52–59. [PubMed]
6. King TD, Mills NL. Nonoperative closure of atrial septal defects. Surgery. 1974;75(3):383–388. [PubMed]
7. Du Z-D, Hijazi ZM, Kleinman CS, Silverman NH, Larntz K. Comparison between transcatheter and surgical closure of secundum atrial septal defect in children and adults. J Am Coll Cardiol. 2002;39(11):1836–1844. doi: 10.1016/S0735-1097(02)01862-4. [PubMed] [Cross Ref]
8. Butera G, Carminati M, Chessa M, Youssef R, Drago M, Giamberti A, Pome G, Bossone E, Frigiola A. Percutaneous versus surgical closure of secundum atrial septal defect: comparison of early results and complications. Am Heart J. 2006;151:228–234. doi: 10.1016/j.ahj.2005.02.051. [PubMed] [Cross Ref]
9. Abaci A, Unlu S, Alsancak Y, Kaya U, Sezenoz B. Short and long term complications of device closure of atrial septal defect and patent foramen ovale: meta-analysis of 28142 patients from 203 studies. Catheter Cardiovasc Interv: Off J Soc Card Angiogr Interv. 2013;82(7):1123–1138. doi: 10.1002/ccd.24875. [PubMed] [Cross Ref]
10. Feltes TF, Bacha E, Beekman RH, 3rd, Cheatham JP, Feinstein JA, Gomes AS, Hijazi ZM, Ing FF, de Moor M, Morrow WR, Mullins CE, Taubert KA, Zahn EM. Indications for cardiac catheterization and intervention in pediatric cardiac disease: a scientific statement from the American Heart Association. Circulation. 2011;123(22):2607–2652. doi: 10.1161/CIR.0b013e31821b1f10. [PubMed] [Cross Ref]
11. Lee C, Lim G, Kim WS, Han HS. Clinical characteristics and outcome of incidental atrial septal openings in very low birth weight infants. Neonatology. 2014;105(2):85–90. doi: 10.1159/000356164. [PubMed] [Cross Ref]
12. Naumburg E, Axelsson I, Huber D, Soderstrom L. Some neonatal risk factors for adult pulmonary arterial hypertension remain unknown. Acta Paediatr. 2015 [PubMed]
13. Butera G, De Rosa G, Chessa M, Rosti L, Negura DG, Luciane P, Giamberti A, Bossone E, Carminati M. Transcatheter closure of atrial septal defect in young children: results and follow-up. J Am Coll Cardiol. 2003;42(2):241–245. doi: 10.1016/S0735-1097(03)00589-8. [PubMed] [Cross Ref]
14. Knop M, Szkutnik M, Fiszer R, Białkowska B, Głowacki J, Białkowski J. Transcatheter closure of atrial septal defect in children up to 10 kg of body weight with Amplatzer device. Cardiol J. 2014;21(3):279–283. doi: 10.5603/CJ.a2013.0120. [PubMed] [Cross Ref]
15. Rastogi N, Smeeton NC, Qureshi SA. Factors related to successful transcatheter closure of atrial septal defects using the Amplatzer septal occluder. Pediatr Cardiol. 2009;30(7):888–892. doi: 10.1007/s00246-009-9452-z. [PubMed] [Cross Ref]
16. Crawford GB, Brindis RG, Krucoff MW, Mansalis BP, Carroll JD. Percutaneous atrial septal occluder devices and cardiac erosion: a review of the literature. Catheter Cardiol Interv. 2012;80(2):157–167. doi: 10.1002/ccd.24347. [PubMed] [Cross Ref]
17. Bartakian S, Fagan TE, Schaffer MS, Darst JR. Device closure of secundum atrial septal defects in children <15 kg: complication rates and indications for referral. JACC Cardiol Interv. 2012;5(11):1178–1184. doi: 10.1016/j.jcin.2012.07.009. [PubMed] [Cross Ref]
18. Petit CJ, Justino H, Pignatelli RH, Crystal MA, Payne WA, Ing FF. Percutaneous atrial septal defect closure in infants and toddlers: predictors of success. Pediatr Cardiol. 2013;34(2):220–225. doi: 10.1007/s00246-012-0413-6. [PubMed] [Cross Ref]
19. Karin Gottvall EL, Karin Källén (2015) Graviditeter, förlossningar och nyfödda barn Medicinska födelseregistret 1973–2014 Assisterad befruktning, 1991–2013 (Pregnancies, Deliveries and Newborn Infants The Swedish Medical Birth Register 1973–2014 Assisted Reproduction, treatment 1991–2013). Stockholm
21. Cnattingius S, Ericson A, Gunnarskog J, Kallen B. A quality study of a medical birth registry. Scand J Soc Med. 1990;18(2):143–148. [PubMed]
22. Haycock GB, Schwartz GJ, Wisotsky DH. Geometric method for measuring body surface area: a height-weight formula validated in infants, children, and adults. J Pediatr. 1978;93(1):62–66. doi: 10.1016/S0022-3476(78)80601-5. [PubMed] [Cross Ref]
23. Cardenas L, Panzer J, Boshoff D, Malekzadeh-Milani S, Ovaert C. Transcatheter closure of secundum atrial defect in small children. Catheter Cardiol Interv: Off J Soc Card Angiogr Interv. 2007;69(3):447–452. doi: 10.1002/ccd.21030. [PubMed] [Cross Ref]
24. Dalvi B, Pinto R, Gupta A. Device closure of large atrial septal defects requiring devices > or =20 mm in small children weighing <20 kg. Catheter Cardiol Interv: Off J Soc Card Angiogr Interv. 2008;71(5):679–686. doi: 10.1002/ccd.21450. [PubMed] [Cross Ref]
25. Moore J, Hegde S, El-Said H, Beekman R, 3rd, Benson L, Bergersen L, Holzer R, Jenkins K, Ringel R, Rome J, Vincent R, Martin G. Transcatheter device closure of atrial septal defects: a safety review. JACC Cardiol Interv. 2013;6(5):433–442. doi: 10.1016/j.jcin.2013.02.005. [PubMed] [Cross Ref]
26. Kaya MG, Baykan A, Dogan A, Inanc T, Gunebakmaz O, Dogdu O, Uzum K, Eryol NK, Narin N. Intermediate-term effects of transcatheter secundum atrial septal defect closure on cardiac remodeling in children and adults. Pediatr Cardiol. 2010;31(4):474–482. doi: 10.1007/s00246-009-9623-y. [PubMed] [Cross Ref]
27. Ho TF, Chia EL, Yip WC, Chan KY. Analysis of P wave and P dispersion in children with secundum atrial septal defect. Ann Noninvasive Electrocardiol. 2001;6(4):305–309. doi: 10.1111/j.1542-474X.2001.tb00123.x. [PubMed] [Cross Ref]
28. Vecht JA, Saso S, Rao C, Dimopoulos K, Grapsa J, Terracciano CM, Peters NS, Nihoyannopoulos P, Holmes E, Gatzoulis MA, Athanasiou T. Atrial septal defect closure is associated with a reduced prevalence of atrial tachyarrhythmia in the short to medium term: a systematic review and meta-analysis. Heart. 2010;96(22):1789–1797. doi: 10.1136/hrt.2010.204933. [PubMed] [Cross Ref]
29. McMahon CJ, Feltes TF, Fraley JK, Bricker JT, Grifka RG, Tortoriello TA, Blake R, Bezold LI. Natural history of growth of secundum atrial septal defects and implications for transcatheter closure. Heart. 2002;87(3):256–259. doi: 10.1136/heart.87.3.256. [PMC free article] [PubMed] [Cross Ref]
30. Sharma M, Khera S, Sondhi V, Devgan A. A study to determine the prevalence of pulmonary arterial hypertension in children with down syndrome and congenital heart disease. Med J Armed Forces India. 2013;69(3):241–245. doi: 10.1016/j.mjafi.2012.11.013. [PMC free article] [PubMed] [Cross Ref]
31. Mathew P, Moodie D, Sterba R, Murphy D, Rosenkranz E, Homa A. Long-term follow-up of children with Down syndrome with cardiac lesions. Clin Pediatr. 1990;29(10):569–574. doi: 10.1177/000992289002901003. [PubMed] [Cross Ref]
32. Stoll C, Dott B, Alembik Y, Roth MP. Associated congenital anomalies among cases with Down syndrome. Eur J Med Genet. 2015;12:674–680. doi: 10.1016/j.ejmg.2015.11.003. [PubMed] [Cross Ref]
33. Butera G, Piazza L, Hijazi Z, Chessa M, Carminati M. Transcatheter treatment of perimembranous ventricular septal defect, secundum atrial septal defect and patent ductus arteriosus in a child. J Cardiovasc Med. 2006;7(10):775–778. doi: 10.2459/01.JCM.0000247327.88030.12. [PubMed] [Cross Ref]
34. Masuda M, Kado H, Tanoue Y, Fukae K, Onzuka T, Shiokawa Y, Shirota T, Yasui H. Does Down syndrome affect the long-term results of complete atrioventricular septal defect when the defect is repaired during the first year of life? Eur J Cardio-thoracic Surg. 2005;27(3):405–409. doi: 10.1016/j.ejcts.2004.11.027. [PubMed] [Cross Ref]
35. Tanner K, Sabrine N, Wren C. Cardiovascular malformations among preterm infants. Pediatrics. 2005;116(6):833–838. doi: 10.1542/peds.2005-0397. [PubMed] [Cross Ref]
36. Riggs T, Sharp SE, Batton D, Hussey ME, Weinhouse E. Spontaneous closure of atrial septal defects in premature vs. full-term neonates. Pediatr Cardiol. 2000;21(2):129–134. doi: 10.1007/s002469910020. [PubMed] [Cross Ref]
37. Choi EK, Jung YH, Kim HS, Shin SH, Choi CW, Kim EK, Kim BI, Choi JH. The Impact of Atrial Left-to-right shunt on pulmonary hypertension in preterm infants with moderate or severe bronchopulmonary dysplasia. Pediatr Neonatol. 2015;56(5):317–323. doi: 10.1016/j.pedneo.2014.12.006. [PubMed] [Cross Ref]
38. Zaqout M, De Baets F, Schelstraete P, Suys B, Panzer J, Francois K, Bove T, Coomans I, De Wolf D. Pulmonary function in children after surgical and percutaneous closure of atrial septal defect. Pediatr Cardiol. 2010;31(8):1171–1175. doi: 10.1007/s00246-010-9778-6. [PubMed] [Cross Ref]
39. Wood AM, Holzer RJ, Texter KM, Hill SL, Gest AL, Welty SE, Cheatham JP, Yates AR. Transcatheter elimination of left-to-right shunts in infants with bronchopulmonary dysplasia is feasible and safe. Congenital heart Dis. 2011;6(4):330–337. doi: 10.1111/j.1747-0803.2011.00540.x. [PubMed] [Cross Ref]

Articles from Springer Open Choice are provided here courtesy of Springer